HK Stock MarketDetailed Quotes

09997 KANGJI MEDICAL

Watchlist
  • 5.900
  • +0.240+4.24%
Market Closed Oct 18 16:08 CST
7.14BMarket Cap12.19P/E (TTM)

KANGJI MEDICAL Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

All
YOY yoy
Hide blank lines yoy
(Q6)Jun 30, 2024
(FY)Dec 31, 2023
(Q6)Jun 30, 2023
(FY)Dec 31, 2022
(Q6)Jun 30, 2022
(FY)Dec 31, 2021
(Q6)Jun 30, 2021
(FY)Dec 31, 2020
(Q6)Jun 30, 2020
(FY)Dec 31, 2019
Turnover
13.58%458.41M
17.76%926.02M
21.45%403.59M
13.92%786.37M
4.46%332.32M
34.95%690.26M
49.64%318.12M
1.59%511.49M
--212.59M
42.36%503.47M
Operating income
13.58%458.41M
17.76%926.02M
21.45%403.59M
13.92%786.37M
4.46%332.32M
34.95%690.26M
49.64%318.12M
1.59%511.49M
212.59M
42.36%503.47M
Cost of sales
-16.44%-95.29M
-22.30%-184.82M
-22.86%-81.83M
-18.68%-151.12M
-17.07%-66.61M
-59.13%-127.34M
-62.78%-56.9M
0.34%-80.02M
---34.95M
-24.73%-80.29M
Operating expenses
-16.44%-95.29M
-22.30%-184.82M
-22.86%-81.83M
-18.68%-151.12M
-17.07%-66.61M
-59.13%-127.34M
-62.78%-56.9M
0.34%-80.02M
-34.95M
-24.73%-80.29M
Gross profit
12.86%363.12M
16.68%741.2M
21.09%321.76M
12.85%635.25M
1.72%265.71M
30.47%562.93M
47.06%261.23M
1.96%431.47M
177.63M
46.28%423.18M
Selling expenses
-20.00%-39.06M
-30.86%-69.84M
-36.24%-32.55M
-14.74%-53.37M
-13.73%-23.89M
4.87%-46.52M
9.48%-21.01M
-18.23%-48.89M
---23.21M
-101.67%-41.36M
Administrative expenses
-11.97%-50.85M
-40.69%-100.27M
-37.63%-45.42M
-14.84%-71.27M
-28.26%-33M
20.44%-62.06M
52.36%-25.73M
-204.16%-78M
---54M
10.00%-25.65M
Research and development expenses
27.83%-43.35M
-93.21%-127.55M
-128.60%-60.08M
-83.38%-66.02M
-63.49%-26.28M
-42.75%-36M
-33.11%-16.07M
-45.13%-25.22M
---12.08M
-16.95%-17.38M
Impairment and provision
151.12%842K
-200.95%-1.06M
-157.75%-1.65M
271.66%1.05M
---639K
---614K
----
----
----
----
-Other impairment is provision
151.12%842K
-200.95%-1.06M
-157.75%-1.65M
271.66%1.05M
---639K
---614K
----
----
----
----
Special items of operating profit
14.52%103.52M
24.44%148.56M
564.33%90.4M
2.07%119.38M
-62.24%13.61M
280.19%116.96M
40.96%36.04M
-41.29%30.76M
--25.57M
46.68%52.4M
Operating profit
22.67%334.22M
4.60%591.03M
39.36%272.46M
5.67%565.02M
-16.61%195.51M
72.42%534.69M
105.82%234.46M
-20.73%310.12M
113.92M
49.79%391.19M
Financing cost
47.83%-614K
-20.37%-2.26M
-64.62%-1.18M
-856.63%-1.88M
-568.22%-715K
-366.67%-196K
---107K
---42K
----
----
Share of profits of associates
---5.87M
----
----
----
----
----
----
----
----
----
Earning before tax
20.81%327.73M
4.55%588.77M
39.27%271.28M
5.36%563.14M
-16.88%194.79M
72.38%534.5M
105.72%234.35M
-20.74%310.08M
113.92M
49.79%391.19M
Tax
-23.97%-52.05M
-33.84%-136.48M
-1.67%-41.99M
-31.22%-101.97M
-18.02%-41.3M
-52.59%-77.71M
-43.88%-34.99M
21.00%-50.93M
---24.32M
-72.51%-64.46M
After-tax profit from continuing operations
20.23%275.69M
-1.93%452.3M
49.38%229.3M
0.96%461.17M
-23.00%153.5M
76.26%456.79M
122.51%199.36M
-20.68%259.15M
89.6M
46.00%326.74M
Earning after tax
20.23%275.69M
-1.93%452.3M
49.38%229.3M
0.96%461.17M
-23.00%153.5M
76.26%456.79M
122.51%199.36M
-20.68%259.15M
89.6M
46.00%326.74M
Minority profit
61.16%-10.16M
-194.55%-51.73M
-520.59%-26.16M
---17.56M
---4.22M
----
----
-92.64%8.85M
--8.85M
56.04%120.29M
Profit attributable to shareholders
11.89%285.85M
5.28%504.02M
61.98%255.46M
4.80%478.74M
-20.89%157.71M
82.50%456.79M
146.91%199.36M
21.24%250.3M
80.74M
40.72%206.44M
Basic earnings per share
11.73%0.2439
8.71%0.4308
68.57%0.2183
6.22%0.3963
-20.41%0.1295
42.03%0.3731
36.49%0.1627
30.63%0.2627
0.1192
0.2011
Diluted earnings per share
12.24%0.2439
8.48%0.4299
67.80%0.2173
6.88%0.3963
-19.76%0.1295
42.78%0.3708
36.55%0.1614
29.14%0.2597
0.1182
0.2011
Currency Unit
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
Accounting Standards
HKAS
HKAS
HKAS
HKAS
HKAS
HKAS
HKAS
HKAS
HKAS
HKAS
Audit Opinions
--
Unqualified Opinion
--
Unqualified Opinion
--
Unqualified Opinion
--
Unqualified Opinion
--
Unqualified Opinion
Auditor
--
Ernst & Young
--
Ernst & Young
--
Ernst & Young
--
Ernst & Young
--
Ernst & Young
(Q6)Jun 30, 2024(FY)Dec 31, 2023(Q6)Jun 30, 2023(FY)Dec 31, 2022(Q6)Jun 30, 2022(FY)Dec 31, 2021(Q6)Jun 30, 2021(FY)Dec 31, 2020(Q6)Jun 30, 2020(FY)Dec 31, 2019
Turnover 13.58%458.41M17.76%926.02M21.45%403.59M13.92%786.37M4.46%332.32M34.95%690.26M49.64%318.12M1.59%511.49M--212.59M42.36%503.47M
Operating income 13.58%458.41M17.76%926.02M21.45%403.59M13.92%786.37M4.46%332.32M34.95%690.26M49.64%318.12M1.59%511.49M212.59M42.36%503.47M
Cost of sales -16.44%-95.29M-22.30%-184.82M-22.86%-81.83M-18.68%-151.12M-17.07%-66.61M-59.13%-127.34M-62.78%-56.9M0.34%-80.02M---34.95M-24.73%-80.29M
Operating expenses -16.44%-95.29M-22.30%-184.82M-22.86%-81.83M-18.68%-151.12M-17.07%-66.61M-59.13%-127.34M-62.78%-56.9M0.34%-80.02M-34.95M-24.73%-80.29M
Gross profit 12.86%363.12M16.68%741.2M21.09%321.76M12.85%635.25M1.72%265.71M30.47%562.93M47.06%261.23M1.96%431.47M177.63M46.28%423.18M
Selling expenses -20.00%-39.06M-30.86%-69.84M-36.24%-32.55M-14.74%-53.37M-13.73%-23.89M4.87%-46.52M9.48%-21.01M-18.23%-48.89M---23.21M-101.67%-41.36M
Administrative expenses -11.97%-50.85M-40.69%-100.27M-37.63%-45.42M-14.84%-71.27M-28.26%-33M20.44%-62.06M52.36%-25.73M-204.16%-78M---54M10.00%-25.65M
Research and development expenses 27.83%-43.35M-93.21%-127.55M-128.60%-60.08M-83.38%-66.02M-63.49%-26.28M-42.75%-36M-33.11%-16.07M-45.13%-25.22M---12.08M-16.95%-17.38M
Impairment and provision 151.12%842K-200.95%-1.06M-157.75%-1.65M271.66%1.05M---639K---614K----------------
-Other impairment is provision 151.12%842K-200.95%-1.06M-157.75%-1.65M271.66%1.05M---639K---614K----------------
Special items of operating profit 14.52%103.52M24.44%148.56M564.33%90.4M2.07%119.38M-62.24%13.61M280.19%116.96M40.96%36.04M-41.29%30.76M--25.57M46.68%52.4M
Operating profit 22.67%334.22M4.60%591.03M39.36%272.46M5.67%565.02M-16.61%195.51M72.42%534.69M105.82%234.46M-20.73%310.12M113.92M49.79%391.19M
Financing cost 47.83%-614K-20.37%-2.26M-64.62%-1.18M-856.63%-1.88M-568.22%-715K-366.67%-196K---107K---42K--------
Share of profits of associates ---5.87M------------------------------------
Earning before tax 20.81%327.73M4.55%588.77M39.27%271.28M5.36%563.14M-16.88%194.79M72.38%534.5M105.72%234.35M-20.74%310.08M113.92M49.79%391.19M
Tax -23.97%-52.05M-33.84%-136.48M-1.67%-41.99M-31.22%-101.97M-18.02%-41.3M-52.59%-77.71M-43.88%-34.99M21.00%-50.93M---24.32M-72.51%-64.46M
After-tax profit from continuing operations 20.23%275.69M-1.93%452.3M49.38%229.3M0.96%461.17M-23.00%153.5M76.26%456.79M122.51%199.36M-20.68%259.15M89.6M46.00%326.74M
Earning after tax 20.23%275.69M-1.93%452.3M49.38%229.3M0.96%461.17M-23.00%153.5M76.26%456.79M122.51%199.36M-20.68%259.15M89.6M46.00%326.74M
Minority profit 61.16%-10.16M-194.55%-51.73M-520.59%-26.16M---17.56M---4.22M---------92.64%8.85M--8.85M56.04%120.29M
Profit attributable to shareholders 11.89%285.85M5.28%504.02M61.98%255.46M4.80%478.74M-20.89%157.71M82.50%456.79M146.91%199.36M21.24%250.3M80.74M40.72%206.44M
Basic earnings per share 11.73%0.24398.71%0.430868.57%0.21836.22%0.3963-20.41%0.129542.03%0.373136.49%0.162730.63%0.26270.11920.2011
Diluted earnings per share 12.24%0.24398.48%0.429967.80%0.21736.88%0.3963-19.76%0.129542.78%0.370836.55%0.161429.14%0.25970.11820.2011
Currency Unit CNYCNYCNYCNYCNYCNYCNYCNYCNYCNY
Accounting Standards HKASHKASHKASHKASHKASHKASHKASHKASHKASHKAS
Audit Opinions --Unqualified Opinion--Unqualified Opinion--Unqualified Opinion--Unqualified Opinion--Unqualified Opinion
Auditor --Ernst & Young--Ernst & Young--Ernst & Young--Ernst & Young--Ernst & Young

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
HK
Overall
Symbol
Latest Price
% Chg

No Data